Saphris;治療藥物分析及市場預測

Saphris;治療藥物分析及市場預測 是由出版商GlobalData在2011年07月所出版的。 這份英文市場調查報告書包含Pages: 25 價格從美金2000起跳。

簡介

本報告提供精神分裂症治療藥物的 Saphris 的平台分析及市場預測，市場特徵為首，評估分析競爭，開發平台等，未來市場競爭等資訊，為您概述為以下內容。

1目錄

1目錄

• 1.1 表格一覽
• 1.2 圖的一覽

2簡介

• 2.1 精神分裂症
• 2.2 症狀
• 2.3 精神分裂症市場
• 2.4 流行病學
• 2.5 病因論
• 2.5.1 遺傳的因素
• 2.5.2 環境的因素
• 2.5.3 異常的腦結構
• 2.6 GlobalData 報告指南

3精神分裂症:市場特性

• 3.1 精神分裂症市場
• 3.2 精神分裂症市場預測及 年複合成長率
• 3.3 精神分裂症治療藥物市場推動力
3.3.1 主要上市藥物專利到期
• 3.3.2 逐漸增加的患者群
• 3.3.3 高處方率
• 3.3.4 低患者遵從率
• 3.3.5 高未滿足需求

4精神分裂症的分類

• 4.1 精神分裂症的起始年齡
• 4.1.1 兒童 / 青春期 / 幼兒期精神分裂症
• 4.1.2 成人的精神分裂症
• 4.2 相關症狀
• 4.2.1妄想型精神分裂症
• 4.2.2 錯亂型的精神分裂症
• 4.2.3 緊張型精神分裂症
• 4.2.4 殘餘型精神分裂症
• 4.2.5 未分類症狀疾患

5精神分裂症的治療

• 5.1 問題解決團隊(CRT)
• 5.2 自願及強制羈留
• 5.3 Antipsychotics
• 5.3.1 典型性的 Antipsychotics
• 5.3.2 非典型的 Antipsychotics
• 5.3.3 患有癡呆症相關精神病的老年患者的死亡率的增加

6 Saphris

• 6.1 引進
• 6.2 作用機制
• 6.3 臨床的研究
• 6.4 Saphris 銷售額的影響因素
• 6.4.1 舌下給藥
• 6.4.2 陰性症狀治療的 Saphris 可能性
• 6.4.3 高度成熟的競爭性的市場後進入者
• 6.4.4 與Invega的競爭
• 6.5 藥物評估
• 6.5.1 藥物風險·效益評估
• 6.5.2 競爭的強度
• 6.6 銷售額預測
• 6.6.1 Saphris 目標患者群
• 6.6.2 投藥
• 6.6.3 市場滲透率
• 6.6.4 治療的年度的成本
• 6.6.5 Saphris 銷售額預測

7精神分裂症市場:附錄

• 7.1 市場定義
• 7.2 簡稱
• 7.3 研究調查方法
• 7.4 藥物銷售額預測模式
• 7.5 諮詢方式
• 7.6 免責聲明
• 7.7 情報來源

1.1 表格一覽

• 表格1: Saphris 第三階段臨床實驗結果
• 表格2:藥物風險·效益評估
• 表格3: Saphris 其他競爭公司
• 表格4: Saphris 、年度的治療經費
• 表格5: Saphris 、全球精神分裂症市場，銷售額預測(m美元)
• 表格6: Saphris 、美國的精神分裂症市場，銷售額預測(m美元)
• 表格7: Saphris 、日本的精神分裂症市場，銷售額預測(m美元)

1.2 圖的一覽

• 圖1:增加的精神分裂症的風險
• 圖2:精神分裂症增加的環境因素
• 圖3:全球精神分裂症市場，市場規模預測(10億美元)
• 圖4:根據發病年齡的精神分裂症的分類
• 圖5: Saphris 藥物模型圖表
• 圖6: Saphris 、全球精神分裂症市場，銷售額預測(m美元)
• 圖7: Saphris 、美國的精神分裂症市場，銷售額預測(m美元)
• 圖8: Saphris 、日本的精神分裂症市場，銷售額預測(m美元)
• 圖9: Saphris 、全球精神分裂症市場，主要國家銷售額分佈預測(%)

目錄

Summary

GlobalData's pharmaceuticals report, "Saphris - Analysis and Estimates from 2009 to 2020" provides Saphris sales estimates for US and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Saphris including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Saphris including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2011-2020 for Saphris in each of the seven major markets.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug's performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1. Table of contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Introduction

• 2.1 Schizophrenia
• 2.2 Symptoms
• 2.3 Schizophrenia Market
• 2.4 Epidemiology
• 2.5 Etiology
  • 2.5.1 Genetic Factors
  • 2.5.2 Environmental Factors
  • 2.5.3 Abnormal Brain Structure
• 2.6 GlobalData Report Guidance

3. Schizophrenia: Market Characterization

• 3.1 Schizophrenia Market
• 3.2 Schizophrenia Market Forecasts and CAGR
• 3.3 Drivers of Schizophrenia Therapeutics Market
  • 3.3.1 Patent Expiry of Leading Marketed Drugs
  • 3.3.2 Increasing Patient Pool
  • 3.3.3 High Prescription Rates
  • 3.3.4 Low Patient Compliance Rate
  • 3.3.5 High Unmet Need

4. Classification of Schizophrenia

• 4.1 Age of Onset of Schizophrenia
  • 4.1.1 Pediatric / Adolescent / Childhood Schizophrenia
  • 4.1.2 Adult Schizophrenia
• 4.2 Associated Symptoms
  • 4.2.1 Paranoid Schizophrenia
  • 4.2.2 Disorganized Schizophrenia
  • 4.2.3 Catatonic Schizophrenia
  • 4.2.4 Residual Schizophrenia
  • 4.2.5 Undifferentiated Disorder

5. Treatment for Schizophrenia

• 5.1 Crisis Resolution Teams (CRT)
• 5.2 Voluntary and Compulsory Detention
• 5.3 Antipsychotics
  • 5.3.1 Typical Antipsychotics
  • 5.3.2 Atypical Antipsychotics
  • 5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

6. Saphris

• 6.1 Introduction
• 6.2 Mechanism of Action
• 6.3 Clinical Studies
• 6.4 Factors Affecting Sales of Saphris
  • 6.4.1 Sublingual Administration
  • 6.4.2 Saphris's Potential in Treating Negative Symptoms
  • 6.4.3 Late Entrant in a Highly Mature and Competitive Market
  • 6.4.4 Competition from Invega
• 6.5 Drug Evaluation
  • 6.5.1 Drug Risk Benefit Score
  • 6.5.2 Intensity of Competition
• 6.6 Sales Forecasts
  • 6.6.1 Target Patient Pool of Saphris
  • 6.6.2 Dosing
  • 6.6.3 Market Penetration
  • 6.6.4 Annual Cost of Therapy
  • 6.6.5 Sales Projections of Saphris

7. Schizophrenia Market: Appendix

• 7.1 Market Definitions
• 7.2 Abbreviations
• 7.3 Research Methodology
• 7.4 Drug Sales Estimates Model
• 7.5 Contact Us
• 7.6 Disclaimer
• 7.7 Sources

• Table 1: Phase III Clinical Trial Results of Saphris
• Table 2: Drug Risk Benefit Score
• Table 3: Competitors of Saphris
• Table 4: Saphris, Annual Treatment Costs, 2011
• Table 5: Saphris, Schizophrenia, Global, Sales Estimates ($m), 2009-2020
• Table 6: Saphris, Schizophrenia, The US, Sales Estimates ($m), 2009-2020
• Table 7: Saphris, Schizophrenia, Japan, Sales Forecasts ($m), 2014-2020

• Figure 1: Risk of Developing Schizophrenia
• Figure 2: Environmental Factors in the Development of Schizophrenia
• Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 2010-2020
• Figure 4: Classification of Schizophrenia based on the Age of Disease Onset
• Figure 5: Drug Model Diagram of Saphris
• Figure 6: Saphris, Schizophrenia, Global, Sales Estimates($m), 2009-2020
• Figure 7: Saphris, Schizophrenia, The US, Sales Estimates($m), 2009-2020
• Figure 8: Saphris, Schizophrenia, Japan, Sales Forecasts($m), 2014-2020
• Figure 9: Saphris, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2018

相關商品

處方藥相關市場調查報告書

抗高血壓藥市場(∼2017年):暢銷藥物(Diovan，Micardis，Avapro，Atacand等)的專利失效加速損耗
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
價格 : US $ 3500
出版日期 : 2012年03月

全球的皮膚科處方藥市場：第8版（抗痘、抗老化、皮膚炎、脫毛、乾癬、皮膚癌、肝斑以及皮脂漏的治療）
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
價格 : US $ 3995
出版日期 : 2012年03月

FDA的Bydureon的認證:醫生的見解
Bydureon FDA Approval: Physician Opinion
價格 : US $ 3800
出版日期 : 2012年02月

GlobalData發行的製藥相關市場調查報告書

肺支氣管發育不良:全球臨床實驗檢討

Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

病毒性呼吸道感染疾病:全球臨床實驗檢討

Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

心搏過速 (快速心律不整):全球臨床實驗檢討

Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!